ANI Pharmaceuticals, Inc. ANIP
71.44 USD +0.38 (+0.53%)
At closeNov 13, 2026, 5:25 PM EST
71.44 0.00 0.00%
After hours · Nov 13, 5:25 PM ET
70.37 Day range 72.00
67.14 52-week range 87.76
- YTD
- -9.50%
- 1 year
- -15.51%
News
seekingalpha.com ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO…
benzinga.com Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121 Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $119 to $121.
benzinga.com ANI Pharmaceuticals Q3 2026 Earnings Call Transcript ANI Pharmaceuticals (NASDAQ:ANIP) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com ANI Pharmaceuticals Q3 Adj. EPS $2.70 Beats $2.18 Estimate, Sales $290.800M Beat $280.196M Estimate ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.70 per share which beat the analyst consensus estimate of $2.18 by 23.85 percent. This is a 32.35 percent increase over earnings of…- benzinga.com ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B Est ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 analyst estimate. Narrows FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.085…
benzinga.com ANI Pharmaceuticals Announces Offer At SEK 11.25 Per Share, About SEK 5.6B ($560M), To Acquire Egetis Therapeutics, Expanding Rare Disease Business Egetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder,…
benzinga.com ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules are the…- benzinga.com Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85 Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.
- benzinga.com ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension Approval for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®."The…
benzinga.com These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.
benzinga.com Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119 Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.- benzinga.com Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90 Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.
benzinga.com ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080…- benzinga.com ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 by 7.8 percent. This is a 22.78 percent increase over earnings of…
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.- benzinga.com Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91 Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold rating and announces Price Target of $91.
- benzinga.com ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter…
benzinga.com ANI Pharmaceuticals Reveals Trial Court Denied Company’s Motion For A New Trial And Judgment As A Matter Of Law For Unjust Enrichment; Co. Intends To Appeal Rulings To The Delaware Supreme Court And Continue To Seek To Recover The Value Of The Assets It Sold To CG Oncology In 2010 Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover…- benzinga.com ANI Pharmaceuticals Announces Topline Data From Its Phase 4 SYNCHRONICITY Clinical Trial Of The Fluocinolone Acetonide Intravitreal Implant; Trial Met Both Co-Primary Endpoints ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide…
- benzinga.com Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.
- benzinga.com ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 Est; Raises FY2026 Sales Guidance from $1.055B-$1.115B to $1.080B-$1.140B vs $1.050B Est. ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 analyst estimate. Raises FY2026 sales outlook from $1.055 billion-$1.115 billion to $1.080…
- benzinga.com ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate. ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.30 by 56.49 percent. This is a 20.59 percent increase over earnings of…
- benzinga.com ANI Pharmaceuticals Announces Launch Of Pimozide Tablets 1 Mg And 2 Mg, Generic Version Of Reference Listed Drug Orap, With 180-Day CGT Exclusivity ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic version of the reference listed drug…
benzinga.com ANI Pharma Launches Isosorbide Mononitrate Tablet USP, Generic Version Of Reference Listed Drug Monoket ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application…- benzinga.com ANI Pharma Announces Publication Of Results From NEW DAY Clinical Trial Involving ILUVIEN For Use In Patients With Diabetic Macular Edema In Ophthalmology, The Journal Of The American Academy Of Ophthalmology ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal…
benzinga.com Earnings Scheduled For February 27, 2026 
benzinga.com Earnings Scheduled For November 7, 2025 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For August 8, 2025
- benzinga.com Delaware Court Gives Unanimous Verdict Detailing That CG Oncology Will Owe No Future Royalties Or Other Payments To ANI Pharmaceuticals CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder…
- benzinga.com Earnings Scheduled For May 9, 2025
benzinga.com Earnings Scheduled For February 28, 2025 
benzinga.com Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - benzinga.com This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
- benzinga.com Earnings Scheduled For February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
- benzinga.com Earnings Scheduled For November 8, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For August 9, 2023 Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.
- benzinga.com Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
- benzinga.com Earnings Scheduled For May 8, 2023 Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
- benzinga.com Earnings Scheduled For March 9, 2023 Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 9, 2022 Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly earnings at $0.11 per share on revenue of $103.46 million.
- benzinga.com Earnings Scheduled For August 8, 2022 Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
- benzinga.com Earnings Scheduled For May 10, 2022 Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
- benzinga.com 68 Biggest Movers From Yesterday Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft…
- benzinga.com 38 Stocks Moving In Tuesday's Mid-Day Session Gainers
- benzinga.com Earnings Scheduled For March 15, 2022 Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million.
- benzinga.com Earnings Scheduled For November 1, 2021 Companies Reporting Before The Bell • ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For August 6, 2021 Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million.
- benzinga.com Earnings Scheduled For May 7, 2021 Companies Reporting Before The Bell • Cronos Group (NASDAQ:CRON) is likely to report earnings for its first quarter.